Journal of Inflammation Research,
Journal Year:
2024,
Volume and Issue:
Volume 17, P. 4001 - 4016
Published: June 1, 2024
Abstract:
Inflammatory
cytokines,
interleukin-36
(IL-36),
IL-37,
IL-38
belong
to
IL-1
family.
The
IL-36
subfamily
obtains
pro-
and
anti-inflammatory
effects
on
various
immune
responses.
Cytokine
has
functions
in
immunity,
the
recently
identified
negatively
associated
with
disease
pathogenesis.
To
date,
expression
of
IL-36,
is
reported
dysregulated
osteoarthritis
(OA)
rheumatoid
arthritis
(RA),
may
be
markers
for
arthritis-related
diseases.
Interestingly,
was
different
either
OA
patients
or
animal
models,
IL-36Ra
synovium
RA
patients.
Moreover,
functional
studies
have
demonstrated
significant
role
these
cytokines
progress.
These
processes
were
related
cells
non-immune
cells,
where
regulate
downstream
signalings
then
involve
OA,
development.
In
this
review,
we
comprehensively
discuss
recent
advancements
development
RA.
We
hope
that
targeting
will
become
a
potential
treatment
option
future.
Keywords:
IL-38,
osteoarthritis,
Biosurface and Biotribology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 30, 2024
Abstract
Bionic
lubricant
materials
are
a
class
of
inspired
by
natural
organisms
and
offer
excellent
lubrication
properties
biocompatibility.
In
the
field
sports
medicine,
their
application
opens
up
new
possibilities
for
prevention
treatment
sports‐related
diseases.
The
authors
will
introduce
existing
theoretical
models
friction
in
locomotor
system,
characteristics
advantages
biomimetic
discuss
depth
applications
medicine.
development
bionic
unprecedented
opportunities
medicine
to
provide
more
effective
long‐lasting
options
patients.
Advanced Healthcare Materials,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 20, 2024
Abstract
Developing
effective
antimicrobial
biomaterials
is
a
relevant
and
fast‐growing
field
in
advanced
healthcare
materials.
Several
well‐known
(e.g.,
traditional
antibiotics,
silver,
copper
etc.)
newer
nanostructured,
chemical,
biomimetic
approaches
have
been
researched
developed
recent
years
valuable
knowledge
has
gained.
However,
associated
infections
(BAIs)
remain
largely
unsolved
problem
breakthroughs
this
area
are
sparse.
Hence,
novel
high
risk
potential
gain
needed
to
address
the
important
challenge
of
BAIs.
Antibiotic
free
that
based
on
physical
action
promising,
since
they
reduce
antibiotic
resistance
tolerance.
Here,
selected
examples
reviewed
such
biomaterials,
namely
switchable,
protein‐based,
carbon‐based
bioactive
glass,
considering
microbiological
aspects
The
review
shows
mainly
powerful
tools
control
microbial
growth
at
interfaces.
These
major
clinical
application
for
future
materials
without
promoting
It
also
these
different
complex
processes
mechanisms,
often
nanoscale.
concludes
with
an
outlook
highlights
current
research
questions
biomaterials.
Advanced Drug Delivery Reviews,
Journal Year:
2024,
Volume and Issue:
212, P. 115395 - 115395
Published: July 14, 2024
A
robust
adaptive
immune
response
is
essential
for
combatting
pathogens.
In
the
wrong
context
such
as
due
to
genetic
and
environmental
factors,
however,
same
mechanisms
crucial
self-preservation
can
lead
a
loss
of
self-tolerance.
Resulting
autoimmunity
manifests
in
development
host
organ-specific
or
systemic
autoimmune
diseases,
hallmarked
by
aberrant
responses
tissue
damage.
The
prevalence
diseases
on
rise,
medical
management
which
focuses
primarily
pharmacological
immunosuppression
that
places
patients
at
risk
side
effects,
including
opportunistic
infections
tumorigenesis.
Biomaterial-based
drug
delivery
systems
confer
many
opportunities
address
challenges
associated
with
conventional
disease
management.
Hydrogels,
particular,
protect
encapsulated
cargo
(drug
cell
therapeutics)
from
environment,
afford
their
presentation
controlled
manner,
be
tailored
respond
conditions
support
treatment
via
multiplexed
functionality.
Moreover,
localized
affected
sites
these
approaches
has
potential
concentrate
action
site,
reduce
off-target
exposure,
enhance
patient
compliance
reducing
need
frequent
administration.
Despite
benefits
disease,
biomaterial-based
focus
largely
downstream
effects
hypersensitivity
have
limited
capacity
eradicate
disease.
contrast,
direct
targeting
reactions
uniquely
enables
prophylaxis
arrest
progression
mitigating
basis
autoimmunity.
One
promising
approach
induce
self-antigen-specific
tolerance,
specifically
subdues
damaging
autoreactivity
while
otherwise
retaining
normal
responses.
this
review,
we
will
discuss
hydrogel-based
those
target
head-on.
As
field
continues
advance,
it
expand
range
therapeutic
choices
people
coping
providing
fresh
prospects
better
clinical
outcomes
improved
quality
life.
Journal of Biomedical Materials Research Part B Applied Biomaterials,
Journal Year:
2024,
Volume and Issue:
112(8)
Published: July 17, 2024
Rheumatoid
arthritis
(RA)
requires
therapeutic
approaches
that
alleviate
symptoms
and
inhibit
the
progression
of
joint
damage.
Glucocorticoids
(GCs)
have
been
a
cornerstone
RA
treatment,
yet
their
use
is
often
limited
by
side
effects.
Recent
advancements
suggest
liposome-based
delivery
systems
can
improve
GC
biodistribution,
minimizing
toxicity.
This
study
introduces
an
innovative
tool
for
treatment
using
prednisone-encapsulated
nonphospholipid
liposomes
(NPLs)
in
combination
with
hyaluronic
acid
(HA)
hydrogel.
Our
methodology
involved
incorporating
prednisone
(PR)
palmitic
cholesterol
to
formulate
stable
NPLs
thin-film
hydration
technique.
The
synthesized
PR-NPLs,
characterized
mean
size
150
nm,
demonstrated
uniform
distribution
higher
drug
encapsulation
comparison
conventional
phospholipid
liposomes.
In
vitro
assays
revealed
PR-NPL
markedly
reduced
inflammatory
responses
macrophages.
Additionally,
we
successfully
incorporated
into
HA
hydrogel,
employing
photoinitiated
cross-linking
process.
novel
composite
offered
modulable
PR
release,
governed
degree
hydrogel
cross-linking.
developed
system
presents
promising
advancement
management,
especially
suited
intraarticular
injections.
It
potentially
enables
targeted,
controlled
release
risk
effects,
signifying
significant
improvement
over
existing
therapies.
RSC Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
1(4), P. 592 - 607
Published: Jan. 1, 2024
Rheumatoid
arthritis
(RA)
is
a
long-term
autoimmune
disease
that
causes
irreversible
deformity
of
joints
and
disability
body
parts.
To
avoid
adverse
effects
drugs
the
existing
transdermal
delivery
techniques
can
be
further
developed
or
improved.
British Journal of Hospital Medicine,
Journal Year:
2024,
Volume and Issue:
85(8), P. 1 - 41
Published: Aug. 30, 2024
Osteoarthritis
and
rheumatoid
arthritis,
though
etiologically
distinct,
are
both
inflammatory
joint
diseases
that
cause
progressive
injury,
chronic
pain,
loss
of
function.
Therefore,
long-term
treatment
with
a
focus
on
relieving
symptoms
is
needed.
At
present,
the
primary
for
arthritis
drug
therapy,
oral
intravenous.
Although
significant
progress
has
been
achieved
these
methods
in
alleviating
symptoms,
certain
prominent
drawbacks
such
as
substantial
side
effects
limited
absorption
medications
call
an
urgent
need
improved
delivery
methods.
Injected
hydrogels
can
be
used
system
to
deliver
drugs
cavity
controlled
manner
continuously
release
them,
thereby
enhancing
retention
improve
therapeutic
effectiveness,
which
attributed
desirable
attributes
low
immunogenicity,
good
biodegradability
biocompatibility.
This
review
summarizes
types
injectable
analyzes
their
applications
systems
treatment.
We
also
explored
how
counteract
inflammation,
bone
cartilage
degradation,
oxidative
stress,
while
promoting
regeneration
osteoarthritis
(OA)
(RA).
highlights
new
approaches
developing
OA
RA.
European Journal of Pharmaceutical Sciences,
Journal Year:
2023,
Volume and Issue:
193, P. 106666 - 106666
Published: Dec. 10, 2023
Transdermal
delivery
of
active
ingredients
is
a
challenge
for
pharmaceutical
technology
due
to
their
inadequate
penetration
properties
and
the
barrier
function
skin.
The
necessity
painless,
effective,
topical
therapy
aging
population
growing,
variety
diclofenac
sodium-containing
semi-solid
preparations
are
available
alleviate
symptoms
these
ailments.
Our
purpose
was
formulate
novel
composition
with
higher
drug
content
enhance
release
permeation,
thereby
providing
more
effective
therapy.
Another
goal
maintain
concentration
organic
solvent
mixture
below
30%,
protect
skin
barrier.
Firstly,
literature
market
research
were
conducted,
based
on
which
appropriate
excipients
target
formulation
selected.
Solubility
tests
conducted
binary
ternary
mixtures.
As
result,
optimal
chosen.
Hydrogels
containing
1,
5,
7%
sodium
prepared
stability
formulations
studied
by
microscopic
measurements
cytotoxicity
test
carried
out
components
also.
permeation
investigated
in
different
concentrations.
It
can
be
concluded
that
we
have
succeeded
preparing
topically
applicable
stable
hydrogel
concentration,
release,
improved
than
market.
